Chenguang Biotech Group Co., Ltd. (300138) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Chenguang Biotech Group Co., Ltd.

Why is Chenguang Biotech Group Co., Ltd. ?

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of 9.13% and Operating profit at 7.94% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 10.89% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of 9.13% and Operating profit at 7.94% over the last 5 years

Negative results in Mar 26

NET SALES(HY) At CNY 3,140.74 MM has Grown at -9.73%
INTEREST(Q) At CNY 28.98 MM has Grown at 39.38%
INTEREST COVERAGE RATIO(Q) Lowest at 465.09

Below par performance in long term as well as near term

Along with generating -21.06% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in FMCG)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Chenguang Biotech Group Co., Ltd. for you?

Medium Risk, Low Return

Absolute

Risk Adjusted

Volatility

Chenguang Biotech Group Co., Ltd.

-21.56%

0.41

33.17%

China Shanghai Composite

23.91%

1.73

13.79%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

9.13%

EBIT Growth (5y)

7.94%

EBIT to Interest (avg)

4.66

Debt to EBITDA (avg)

4.87

Net Debt to Equity (avg)

0.90

Sales to Capital Employed (avg)

0.83

Tax Ratio

20.28%

Dividend Payout Ratio

39.29%

Pledged Shares

Institutional Holding

ROCE (avg)

6.79%

ROE (avg)

10.89%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.13

EV to EBIT

18.15

EV to EBITDA

13.43

EV to Capital Employed

1.07

EV to Sales

1.11

PEG Ratio

0.06

Dividend Yield

4.07%

ROCE (Latest)

5.88%

ROE (Latest)

10.37%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

6What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -2.26% (YoY

NET PROFIT(9M)

Higher at CNY 249.34 MM

CASH AND EQV(HY)

Highest at CNY 5,664.56 MM

-14What is not working for the Company

NET SALES(HY)

At CNY 3,140.74 MM has Grown at -9.73%

INTEREST(Q)

At CNY 28.98 MM has Grown at 39.38%

INTEREST COVERAGE RATIO(Q)

Lowest at 465.09

DEBT-EQUITY RATIO (HY)

Highest at 94.25 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.51 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 12.39 times

Here's what is working for Chenguang Biotech Group Co., Ltd.

Net Profit

At CNY 249.34 MM has Grown at 146.12%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CNY MM)

Cash and Eqv

Highest at CNY 5,664.56 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Net Profit

Higher at CNY 249.34 MM

than preceding 12 month period ended Mar 2026

MOJO Watch

In the nine month period the company has already crossed sales of the previous twelve months

Net Profit (CNY MM)

Raw Material Cost

Fallen by -2.26% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Chenguang Biotech Group Co., Ltd.

Interest

At CNY 28.98 MM has Grown at 39.38%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest Coverage Ratio

Lowest at 465.09

in the last five periods

MOJO Watch

The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Sales

At CNY 3,140.74 MM has Grown at -9.73%

Year on Year (YoY)

MOJO Watch

Near term sales trend is negative

Net Sales (CNY MM)

Debt-Equity Ratio

Highest at 94.25 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.51 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 12.39 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio